JP2025502891A5 - - Google Patents

Info

Publication number
JP2025502891A5
JP2025502891A5 JP2024543040A JP2024543040A JP2025502891A5 JP 2025502891 A5 JP2025502891 A5 JP 2025502891A5 JP 2024543040 A JP2024543040 A JP 2024543040A JP 2024543040 A JP2024543040 A JP 2024543040A JP 2025502891 A5 JP2025502891 A5 JP 2025502891A5
Authority
JP
Japan
Prior art keywords
product according
pharmaceutical product
satralizumab
dose
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502891A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2023/001270 external-priority patent/WO2023140269A1/en
Publication of JP2025502891A publication Critical patent/JP2025502891A/ja
Publication of JP2025502891A5 publication Critical patent/JP2025502891A5/ja
Pending legal-status Critical Current

Links

JP2024543040A 2022-01-19 2023-01-18 自己免疫性脳炎のサトラリズマブによる治療 Pending JP2025502891A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263300893P 2022-01-19 2022-01-19
US63/300,893 2022-01-19
PCT/JP2023/001270 WO2023140269A1 (en) 2022-01-19 2023-01-18 Treatment of autoimmune encephalitis with satralizumab

Publications (2)

Publication Number Publication Date
JP2025502891A JP2025502891A (ja) 2025-01-28
JP2025502891A5 true JP2025502891A5 (cg-RX-API-DMAC7.html) 2026-01-14

Family

ID=87348849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543040A Pending JP2025502891A (ja) 2022-01-19 2023-01-18 自己免疫性脳炎のサトラリズマブによる治療

Country Status (11)

Country Link
US (1) US20250127891A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466018A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025502891A (cg-RX-API-DMAC7.html)
KR (1) KR20240145472A (cg-RX-API-DMAC7.html)
CN (1) CN118900699A (cg-RX-API-DMAC7.html)
AU (1) AU2023209259A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243067A1 (cg-RX-API-DMAC7.html)
IL (1) IL314213A (cg-RX-API-DMAC7.html)
MX (1) MX2024008835A (cg-RX-API-DMAC7.html)
TW (1) TW202337495A (cg-RX-API-DMAC7.html)
WO (1) WO2023140269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010065116A2 (en) 2008-12-02 2010-06-10 The Trustees Of The University Of Pennsylvania The use of il-27-p28 to antagonize il-6 mediated signaling
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
JPWO2020202839A1 (cg-RX-API-DMAC7.html) * 2019-03-29 2020-10-08

Similar Documents

Publication Publication Date Title
Egan et al. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine
KR101900520B1 (ko) 복합 조성물
JP2015187125A5 (cg-RX-API-DMAC7.html)
US5817699A (en) Process for the preparation of ketamine ointment
Present the efficacy of infliximab in Crohn’s disease—healing of fistulae
JP2024529434A5 (cg-RX-API-DMAC7.html)
JP2025148449A5 (cg-RX-API-DMAC7.html)
Tumani Corticosteroids and plasma exchange in multiple sclerosis
Van der Bijl et al. Rectal ketamine and midazolam for premedication in pediatric dentistry
Rommer et al. Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions
Vermersch et al. Mycophenolate mofetil and neurological diseases
EP3701956B1 (en) Prophylactic and/or therapeutic agent for dementia
Trobe High-dose corticosteroid regimen retards development of multiple sclerosis in optic neuritis treatment trial
US20040147433A1 (en) Neuroimmunophilins for selective neuronal radioprotection
AU766095B2 (en) Neuroimmunophilins for selective neuronal radioprotection
Huang et al. Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study
CN108014337A (zh) 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物
El Ghazaly et al. Use of Oral Mini Pulse Dexamethasone in Vitiligo Patients
Klein Discontinuation of benzodiazepines in patients with anxiety disorders: a focus on alprazolam and alprazolam extended release
CN114129722B (zh) 注射用人免疫球蛋白在制备预防或治疗辐照损伤的药物中的用途
Sarmiento et al. Guillain-Barre syndrome following 2-chlorodeoxyadenosine treatment for Hairy Cell Leukemia
CN108014336B (zh) 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物
PILLING et al. Electroshock therapy of a depressed patient with complete heart block
RU2233664C2 (ru) Способ лечения красного плоского лишая
NZ781127B2 (en) Mirikizumab for use in a method of treating crohn's disease